Pharma
Fresenius discontinues operation of its digital subsidiary Curlie.
Fresenius continues to drive forward its corporate restructuring efforts in order to strategically realign itself.
Fresenius, a medical corporation and part of the DAX, continues its restructuring course and is divesting from its subsidiary Curalie. This announcement was made on Friday by the hospital company Helios in Bad Homburg, after it had been reported earlier by the "Manager Magazine". According to the announcement, the operations of the parent company Curalie GmbH, as well as almost all of its subsidiaries, will be discontinued by the end of 2023. However, the subsidiaries Meditec and Ibs are planned to be sold.
According to the company, this is not a limitation of Fresenius' digitization ambitions, as digitization will continue to be a focus of the company. Helios, the largest hospital operator in Germany with nearly 90 clinics, will increasingly focus on digitizing its core activities in inpatient and outpatient healthcare. For example, artificial intelligence will be used to support decision-making. The management has already taken measures to promote the implementation and exploration of new digital strategies.
The decision to close Curalie is part of a larger plan to get the company back on track. For over a year, acting CEO Michael Sen has been focusing more on the business sector and restructuring the highly indebted DAX group. In the spring, he had already announced plans to divest from several business areas. In the meantime, a hospital in Peru and the fertility clinics of the Eugin group have been sold. According to recent press reports, approximately 60 rehabilitation centers and some nursing homes of the Austrian subsidiary Vamed are also up for sale, with a total value of 600 to 800 million euros. However, Fresenius declined to comment on this matter when asked.
On the stock exchange, the Fresenius share reacted with a temporary decline of 1.64 percent to 28.11 euros via XETRA. However, investors still seem to have confidence in the company's restructuring course.
Fresenius focuses on its core business and digitization with the sale of Curalie and other areas to bring the company back on track to success. Only time will tell if this plan is successful and the company becomes stronger again.
